

Göttingen, Germany | October 20, 2025

Sartorius hosts CGT forum in Boston to drive innovation in Cell & Gene Therapies

- The forum spotlights data analytics, AI-driven solutions, regulatory perspectives, and more
- It addresses scalability, process control, and availability of transformative therapies
- It reinforces the company's role as a strong collaborator in biomanufacturing

Sartorius, a leading life science company, will host the Sartorius Cell & Gene Therapy (CGT) Forum in Boston, Massachusetts on October 23. The event will convene key opinion leaders and subject matter experts from across the research and manufacturing landscape. The talks and presentations will explore how cutting-edge technologies, regulatory insights, and investment strategies are shaping the future of cell and gene therapies — and driving scalability, process control, and cost-effective availability of these transformative treatments.

The CGT Forum will highlight three key themes shaping the future of the field:

- The transformative role of data analytics: From early-stage R&D to scalable manufacturing and patient access, experts will showcase how data is setting new benchmarks for efficiency, quality, and impact across the CGT value chain
- Accelerating innovation in CGT: Attendees will learn about breakthrough technologies and novel processes transforming the cell, gene, and nucleic acids landscape
- Shaping the next chapter of the CGT industry: Peers and thought leaders will connect to explore emerging trends, technologies, and approaches that will define the next generation of cell and gene therapies

Altogether, the forum aims to provide attendees with insights for enhancing scalability and control, ultimately improving access to cell and gene therapies. In addition, the forum will feature expert-led sessions on regulatory perspectives, AI-driven analytics, and start-up and investment strategies fueling growth in the sector. "As cell and gene therapies transition from promise to practice, the industry must unite to overcome shared challenges and seize new opportunities," said Maurice Phelan, President of Sartorius North America. "The Sartorius CGT Forum is designed to foster those conversations, bringing the brightest minds together to accelerate innovation and impact."

Cédric Volanti, Head of ATS said, "The cell and gene therapy field is at a pivotal moment, and technological advancements are critical to making these life-changing therapies more affordable and accessible."

Full agenda, speaker lineup, and registration details:

<https://www.sartorius.com/en/company/exhibition-conferences/local-events/cgt-forum-2025-boston#id-1739908>

A profile of Sartorius

Sartorius is a leading international partner to life sciences research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group's Lab Products & Services Division focuses on laboratories performing research and quality control at pharmaceutical and biopharmaceutical companies as well as academic research institutes. The Bioprocess Solutions Division, with its broad product portfolio focusing on single-use solutions, helps customers manufacture biotech medications, vaccines, and cell and gene therapies more safely, rapidly, and sustainably. Based in Göttingen, Germany, the company has a strong global reach with around 60 production and sales sites worldwide. Sartorius regularly expands its portfolio through the acquisition of complementary technologies. In 2024, the company generated sales revenue of around 3.4 billion euros. More than 13,500 employees work for customers around the globe.

Visit our [Newsroom](#) or follow us on [LinkedIn](#).

Contact

Lars Hanf
Head of Marketing BPS
+491759558820
Lars.Hanf@Sartorius.com